Triumeq
indicated for HIV infection to support viral suppression.
Strengths: 600/50/300mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Antiretroviral Combination
- Pharmacological class
NRTI + Integrase Inhibitor
- Minor side effects
insomnia; headache; fatigue
- Moderate side effects
nausea; diarrhoea; dizziness; abnormal dreams
- Dosage forms
Tablet
- Administration route
Oral use
- Patient summary
indicated for HIV infection to support viral suppression.
- Prescription status
POM
- Manufacturer
ViiV Healthcare
- Onset Time
1–2 hours
- Duration
24 hours
- Storage instructions
Store below 30°C. Keep bottle tightly closed.
- Drug interactions
metformin; calcium supplements; iron supplements; magnesium antacids
- Age restrictions
Use in adolescents and adults as per weight guidelines.
Contraindications
hypersensitivity to abacavir; hypersensitivity to dolutegravir; hypersensitivity to lamivudine; severe hepatic impairment
Precautions and warnings
hypersensitivity reaction (screen for HLA-B*5701 prior to use); monitor for rash; do not discontinue without medical supervision
Serious side effects
hypersensitivity reaction — requires immediate medical attention; lactic acidosis — requires immediate medical attention; hepatic toxicity — requires immediate medical attention
Mechanism of action
Triumeq combines three antiretroviral agents that inhibit HIV replication by targeting different stages of the viral life cycle. This triple action effectively maintains low viral loads and supports long-term health.
Pregnancy and breastfeeding
Pregnancy: Use only if potential benefit outweighs risk. Breastfeeding: Not recommended.
Triumeq
indicated for HIV infection to support viral suppression.
Editorial Notes
- Active ingredient(s): Abacavir, Dolutegravir, Lamivudine
- Listed indication(s): HIV Infection
Available option
- 30 tablets - 600/50/300 mg1505-600-50-300-mg-18061